지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.7
- 수록면
- 543 - 550 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to elucidate the treatment rate, factors affecting treatment decisions, and efficacy of interferon- based therapy in a real-world setting. Methods: This nationwide cohort study included 1,191 newly diagnosed patients with chronic HCV infection at seven tertiary hospitals in South Korea. Subjects were followed retrospectively until March 2015, which was just before the approval of DAA therapy.
Results: In total, 48.2% and 49.3% of the patients had HCV genotypes 1 and 2, respectively. Interferon-based therapy was initiated in 541 patients (45.4%). The major reasons for no treatment included ineligibility (18.9%), concern about adverse events (22.3%), cost (21.5%), and an age >75 years (19.5%). Interferon-based therapy was discontinued (18.5%) mainly due to adverse events (n=66). The intent-to-treat analysis found that the sustained virologic response (SVR) rate was 58.3% in genotype 1 patients and 74.7% in nongenotype 1 patients. Conclusions: Approximately one-third of newly diagnosed HCV patients in South Korea received interferon-based therapy and showed a suboptimal SVR rate. Diagnosis of patients at younger ages and with a less advanced liver status and reducing the DAA therapy cost may fulfill unmet needs.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Mohd Hanafiah K / 2013 / Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence / Hepatology 57:1333~1342
Stanaway JD / 2016 / The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 / Lancet 388:1081~1088
Wedemeyer H / 2014 / Strategies to manage hepatitis C virus (HCV) disease burden / J Viral Hepat 21(Suppl 1):60~89
Lyoo K / 2011 / Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin / J Clin Virol 52:363~366
정석후 / 2012 / Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C / Clinical and Molecular Hepatology 18(4):360~367
Stanaway JD / 2016 / The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 / Lancet 388:1081~1088
Wedemeyer H / 2014 / Strategies to manage hepatitis C virus (HCV) disease burden / J Viral Hepat 21(Suppl 1):60~89
Lyoo K / 2011 / Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin / J Clin Virol 52:363~366
정석후 / 2012 / Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C / Clinical and Molecular Hepatology 18(4):360~367
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Gut and Liver
2017 .01
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Highly Effective Peginterferon α-2a plus Ribavirin Combination Therapy for Chronic Hepatitis C in Hemophilia in Korea
Clinical and Molecular Hepatology
2015 .01
-
Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
Clinical and Molecular Hepatology
2017 .01
-
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
2019 .01
-
Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data
Gut and Liver
2017 .01
-
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Journal of Korean Medical Science
2019 .01
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
Gut and Liver
2015 .01
-
Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study
Gut and Liver
2020 .01
-
HCV, Interferon Therapy Response, Direct Acting Antiviral Therapy Revolution and Pakistan: Future Perspectives
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
Journal of Korean Medical Science
2019 .01
-
Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study
Gut and Liver
2016 .01
-
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Clinical and Molecular Hepatology
2020 .01
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
Gut and Liver
2016 .01
-
Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea
Gut and Liver
2017 .01
-
Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Gut and Liver
2020 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0